S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

$3.45
-0.02 (-0.58%)
(As of 03/28/2024 ET)
Today's Range
$3.39
$3.54
50-Day Range
$1.31
$3.70
52-Week Range
$0.97
$4.00
Volume
117,188 shs
Average Volume
300,717 shs
Market Capitalization
$237.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67

Trevi Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
122.2% Upside
$7.67 Price Target
Short Interest
Healthy
1.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Trevi Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.39) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

329th out of 939 stocks

Pharmaceutical Preparations Industry

154th out of 444 stocks

TRVI stock logo

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

TRVI Stock Price History

TRVI Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trevi Therapeutics: Q4 Earnings Insights
Trevi Therapeutics to Participate in Upcoming March Events
Trevi Therapeutics Inc.
TRVI Mar 2024 2.000 call
TRVI Mar 2024 3.000 call
Trevi Therapeutics Inc (TRVI)
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.67
High Stock Price Target
$9.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+122.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.29 per share

Miscellaneous

Free Float
50,024,000
Market Cap
$237.91 million
Optionable
Optionable
Beta
0.85
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Ms. Jennifer L. Good (Age 59)
    Co-Founder, CEO, President & Director
    Comp: $781.85k
  • Dr. Thomas R. Sciascia M.D. (Age 71)
    Co-Founder & Chief Science Officer
    Comp: $530.48k
  • Dr. David J. Clark A.F.P.M. (Age 59)
    M.D., M.R.C.P., Chief Medical Officer
    Comp: $325.39k
  • Ms. Lisa Delfini (Age 54)
    Chief Financial Officer
  • Mr. Christopher Galletta (Age 46)
    Controller & Chief Accounting Officer
  • Katie McManus
    Communications Manager
  • Mr. Farrell Simon Pharm.D.
    Chief Commercial Officer
  • Ms. Danine Summers (Age 66)
    Vice President of Medical Affairs

TRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings
or view top-rated stocks.

What is Trevi Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 1 year price targets for Trevi Therapeutics' stock. Their TRVI share price targets range from $6.00 to $9.00. On average, they predict the company's share price to reach $7.67 in the next year. This suggests a possible upside of 122.2% from the stock's current price.
View analysts price targets for TRVI
or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2024?

Trevi Therapeutics' stock was trading at $1.34 at the start of the year. Since then, TRVI stock has increased by 157.5% and is now trading at $3.45.
View the best growth stocks for 2024 here
.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TRVI earnings forecast
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its earnings results on Wednesday, November, 10th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.01. During the same period last year, the business earned ($0.41) earnings per share.

What other stocks do shareholders of Trevi Therapeutics own?
When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (11.56%), Opaleye Management Inc. (3.97%), Vanguard Group Inc. (3.51%), Vanguard Group Inc. (3.51%), Bridgeway Capital Management LLC (0.33%) and BNP Paribas Financial Markets (0.21%). Insiders that own company stock include Lisa Delfini, Paul Edward Walker and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners